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ABSTRACT
Objectives: High potassium intake could prevent
stroke, but supplementation is considered hazardous.
We assessed the effect of oral potassium
supplementation on serum or plasma potassium levels
and renal function.
Setting: We updated a systematic review of the effects of
potassium supplementation in randomised clinical trials
carried out worldwide, published in 2013, extending it to
July 2015. We followed the PRISMA guidelines.
Participants: Any individual taking part in a potassium
supplementation randomised clinical trial. Studies
included met the following criteria: randomised clinical
trials, potassium supplement given and circulating
potassium levels reported.
Intervention: Oral potassium supplementation.
Primary outcome measures: Serum or plasma
potassium and serum or plasma creatinine.
Results: A total of 20 trials (21 independent groups)
were included (1216 participants from 12 different
countries). All but 2 were controlled (placebo n=16,
control n=2). Of these trials, 15 were crossover, 4 had a
parallel group and 1 was sequential. The duration of
supplementation varied from 2 to 24 weeks and the
amount of potassium given from 22 to 140 mmol/day. In
the pooled analysis, potassium supplementation caused a
small but significant increase in circulating potassium
levels (weighted mean difference (WMD) 0.14 mmol/L,
95% CI 0.09 to 0.19, p<1×10−5), not associated with
dose or duration of treatment. The average increase in
urinary potassium excretion was 45.75 mmol/24 hours,
95% CI 38.81 to 53.69, p<1×10−5. Potassium
supplementation did not cause any change in circulating
creatinine levels (WMD 0.30 µmol/L, 95% CI −1.19 to
1.78, p=0.70).
Conclusions: In short-term studies of relatively healthy
persons, a moderate oral potassium supplement resulted
in a small increase in circulating potassium levels and no
change in renal function.
BACKGROUND
A high potassium (K) intake lowers blood
pressure (BP) in people with hypertension
and, to a lesser extent, in people with
normal BP.1 2 However, the beneﬁcial effects
of K extend beyond BP, and it may include a
reduction in the risk of stroke (independent
of BP changes).1 3 4
The K intake in the Western world is rela-
tively low,4 and a lower K intake has been
associated with increased risks of cardiovascu-
lar disease, especially stroke.1 3 In rando-
mised controlled trials (RCTs), a moderate
increase in K intake, either as supplement or
with diet, reduces BP,1 2 and the WHO has
recently issued global recommendations for
a target dietary K intake of ≥90 mmol/day
(≥3510 mg/day) for adults.5 6
Strengths and limitations of this study
▪ This is the first study evaluating the safety of
increasing potassium intake with supplements
on circulating potassium and renal function,
based on randomised controlled trials.
▪ As none of the trials had serum–plasma potas-
sium and creatinine as primary outcomes, the
studies may have been underpowered for an
effect on these variables.
▪ The results are only generalisable to the type of
patients and individuals who took part in the
trials considered (people with hypertension, with
and without therapy, normotensives, high-risk
groups, non-smokers and random sample of the
general population).
▪ The source of heterogeneity was identified.
However, the removal of the heterogeneity did
not alter substantially the pooled estimate.
▪ The study shows that a short-term moderate
increase in potassium intake using supplements
(average 45 mmol or 1755 mg/day; range 22–
140 mmol or 858–5460 mg/day) is safe and
void of risk of hazardous hyperkalaemia or renal
deterioration in healthy people and patients, even
using blockers of the renin–angiotensin system,
whose kidney function is not impaired.
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Different approaches may be adopted to achieve a
minimum daily K intake.7 They are dietary modiﬁcation,
use of salt substitutes and K supplementation. Dietary
modiﬁcations would involve substituting potassium-low
foods with fruits, vegetables, beans and nuts.8 They would
be appropriate for population-based primary prevention
strategies, although it is generally costly and not always
equitable. Salt substitutes are commercially available salt
mixtures, in which the proportion of sodium chloride is
substituted with K and magnesium salts.9 Their use
reduces BP and sodium consumption, concurrently
increasing K intake.10 This strategy is being considered in
China to reduce hypertension.11 12 Supplementation with
a K salt represents a cheap intervention to achieve a
minimum daily target.1 It is acceptable to many patients
and has been advocated as a potential cost-effective
adjunct in the secondary prevention of stroke.7
However, there have been concerns that a widespread
moderate increase in K, especially when given as supple-
mentation, could be harmful, leading to hazardous
hyperkalaemia.2 13–15 Furthermore, the proposal of
replacing sodium chloride with K-based salt in food
manufacturing has also been opposed as potentially
harmful.16 17
Given the potential usefulness and cost-effectiveness of
K supplementation, we decided to update the most com-
prehensive systematic review carried out to date on the
effects of K supplements on a variety of cardiovascular
and biochemical outcomes.1 However, at the time
neither circulating K nor creatinine levels were included
in the outcomes of interest. We therefore carried out an
updated systematic review and a meta-analysis of RCTs of
K supplementation using the same search strategy to
estimate the effects that moderate supplementation of K
has on serum levels and renal function.
DATA AND METHODS
Study selection
We updated a systematic review carried out as part of a
WHO review of the effects of K on cardiovascular risk
factors, published in 2013.1 We replicated the search strat-
egy outlined in the paper extending it to papers pub-
lished from 25 August 2011 to 10 July 2015. The search
strategy is shown in online supplementary S1. We kept the
same criteria as originally deﬁned. In brief, we planned to
include only RCTs (individual and cluster randomised).
RCTs must have allocated at least one group of partici-
pants to increased K intake (intervention) and one group
to lower K intake (control) for at least 4 weeks. RCTs had
to use urinary K excretion from 24-hour urine collections
to estimate actual K intake. The RCTs could not have con-
comitant interventions (ie, non-drug interventions, anti-
hypertensive drugs or other drugs) in the intervention
group unless those interventions were also applied to the
control group, so the only difference between the groups
was the level of K intake. We excluded studies targeting
acutely ill or HIV-positive people, people admitted to
hospital or people with impaired urinary K excretion due
to a medical condition or drug treatment. The searches
were run on MEDLINE and Embase with no language
restriction. After downloading the abstracts and deleting
duplicates, abstracts were scanned. We also included 25
articles selected from the original WHO search.1 Studies
that met the following inclusion criteria were then
selected for the present analysis: (1) RCTs, (2) the inter-
vention group should be K supplement and (3) serum or
plasma K levels should be reported. A total of 20 studies
were included (13 from the papers published from 2011
to 2015 and 7 from the previous review; ﬁgure 1 and see
online supplementary S2 and S3). The systematic review
and the meta-analysis followed the PRISMA guidelines
(see online supplementary Checklist).
Data extraction, risk of bias and quality assessment
Data extraction was performed in duplicate to counteract
human errors and individual biases (LAB and FPC). In
addition to extracting relevant data on K supplementa-
tion, serum or plasma K and creatinine levels, urinary
sodium and K excretions, information was gathered from
individual studies to compose a study characteristics table
(table 1) which incorporated descriptive and methodo-
logical details about the design of the trials, treatment
tested and outcomes measured. When data or copies
were not available, authors were contacted to provide
information. Data extraction sheets were checked by the
review team, and differences were resolved by discussion.
For the meta-analysis, means and SDs of outcome mea-
sures were extracted for the K supplementation and
control groups at the end of each intervention period
(for crossover studies), and for baseline and post-
treatment period (for parallel-group studies). We
assessed the risk of bias quantitatively using the rating
scale developed by Downs and Black18 (table 1 and see
online supplementary S4) and qualitatively using the
Cochrane Collaboration’s tool19 (see online supplemen-
tary S5 and S6). For RCTs, we assessed the risk of bias
associated with the method of sequence generation (pos-
sible selection bias), allocation concealment (possible
selection bias), blinding (possible performance bias),
selective reporting (possible selective reporting bias), loss
to follow-up (possible attrition bias) and completeness of
reporting outcome data (possible attrition bias). We
rated the risk of bias as being low, unclear or high accord-
ing to established PRISMA criteria. We used funnel plots
to assess the presence of small study bias. We generated
‘risk of bias graph’ and ‘risk of bias summary’ ﬁgures (see
online supplementary S5 and S6).
Data synthesis and analysis
Comparisons were made between the K supplementa-
tion and control groups with reference to the change
between post-treatment groups in crossover trials and
differences in changes from baseline to post-treatment
groups in parallel-group trials. Changes were calculated
such that a positive difference represents an increase
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and a negative difference a reduction in the outcome
measure in the K-supplemented group compared to
placebo or control. Weighted mean differences (WMDs)
between the effect of treatment and control were esti-
mated using a random-effect model.20 The random-
effects method incorporates an assumption that the
different studies are estimating different, yet related,
intervention effects. The method is based on the inverse-
variance approach, making an adjustment to the study
weights according to the extent of variation, or hetero-
geneity, among the varying intervention effects. For each
outcome, data from all trials were entered into a funnel
plot. Asymmetry of the plot was visually examined and
formally tested by Egger’s test21 to detect publication
bias. Statistical heterogeneity among studies was assessed
by χ2 test and the I2 statistic.22 Comparisons with signiﬁ-
cant heterogeneity were followed up by sensitivity analysis
in which one study was omitted at a time to identify the
source of heterogeneity. If dropping the ﬁrst study did
not reduce heterogeneity to a non-signiﬁcant level, a
second study was removed, and so on. Subgroup analyses
were also carried out to examine sources of heterogeneity
attributable to the study characteristics. Exploratory
groups were deﬁned a priori to compare the effect of K
supplementation according to sex, age groups, ethnicity,
dose of K and duration of supplementation. All statistical
analyses were performed using RevMan v.5.3.5. and
STATA V.14.1.
RESULTS
Twenty-one samples from the 20 studies were includeds1–s20
(ﬁgure 1 and see online supplementary S2). Excluded
studies are listed in online supplementary S3.
Characteristics of the trials
Eighteen studies recruited men and women, whereas
two studies recruited only women.s7 s10 Two studies only
studied black participantss7 s11 (table 1). They included
1216 participants from 12 different countries (6 from
UK, 3 from The Netherlands, 2 each from New Zealand
and India, 1 from USA, South Africa, Italy, Australia,
Kenya, Chile, Japan and Northern Ireland). All but
2s3 s18 were controlled with either placebo (n=16) or a
control intervention (n=2; table 1). Fifteen used a cross-
over design, four had a parallel group and one was
sequential. All studies used K chloride as supplement,
and one had an additional arm with K bicarbonate.s17
The duration of supplementation varied from 2 to
Figure 1 PRISMA flow diagram.
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Table 1 Characteristics of the studies included in the meta-analysis
Author
(year) Country Population
Participants
(n)
Age
(range),
years Design Quality* Control Potassium
Duration
(weeks)
Quantity
of K
(mmol/day)
Urinary K
(mmol/day)
Plasma/
serum K
(mmol/L) Comment
MacGregor
(1982)
UK HPT 23
12 men;
18 white
45 (26–66) RCT-DBX 25 Placebo KCl (slow-K) 4 64 Pl: 62
K: 118
Pl: 3.84
K: 4.02
Richards
(1984)
New
Zealand
HPT 12 (19–52) RCT-X
(not
blinded)
23 Control diet KCl (elixir) 4 140 C: ∼60
K: ∼170
C: 3.84
K: 3.99
Control diet
180 Na/ 60 K
Bulpitt
(1985)
UK HPT 33 (K=14;
C=19)
55% women
55 RCT-P
(open)
21 No
supplement
KCl (slow-K) 12 64 C: 55
K: 95
C: 3.5
K: 3.8
On loop
diuretics
Kaplan
(1985)
USA HPT with
hypokalaemia
16
10 women;
13 black
48.8 (35–66) RCT-DBX 25 Placebo KCl 6 60 Pl: 36
K: 82
Pl: 3.00
K: 3.56
Hypokalaemic
on diuretics
Smith
(1985)
UK HPT 20
11 men; 18
white
53 (30–66) RCT-DBX 26 Placebo KCl (slow-K) 4 64 Pl: 67
K: 117
Pl: 3.9
K: 4.1
Reduced Na to
70
Zoccali
(1985)
UK HPT 19
10 men
M: 41 (26–53)
W: 35 (26–53)
RCT-SBX 20 Placebo
(lactose)
KCl (Selora) 2 100 Pl: 58
K: 139
Pl: 3.9
K: 4.0
Selora (92%
KCl, 6% K
gluconate, 1%
Ca silicate, 1%
glutamic acid)
Matlou
(1986)
South
Africa
HPT 32
Black women
51 (34–62) RCT-SBX 21 Placebo
(teaspoon
as glucose)
KCl (teaspoon
as salt)
6 65 Pl: 52
K: 114
Pl: 3.87
K: 4.32
Grobbee
(1987)
The
Netherlands
HPT 40
34 men
(18–28) RCT-DBX 23 Placebo KCl (slow-K) 6 72 Pl: 74
K: 131
Pl: 3.76
K: 4.00
Na restriction
Siani
(1987)
Italy HPT 37
23 men
45 (21–61) RCT-DBP 25 Placebo KCl
(Lento-Kalium)
15 48 Pl: 57
K: 87
Pl: 4.4
K: 4.3
Barden
(1987)
Australia NT 44
women
(18–55) RCT-DBX 20 Placebo KCl (slow-K) 4 80 Pl: ∼55
K: ∼115
Pl: 3.725
K: 3.86
Dietary K
<60 mmol/day
Obel
(1989)
Kenya HPT 48
black
40 RCT-DBP 21 Placebo KCl (slow-K) 16 64 Pl: 62
K: 102
Pl: 4.0
K: 4.0
Patki
(1990)
India HPT 37
8 men
49.9 RCT-DBX 24 Placebo KCl (Kesol B,
liquid)
8 60 Pl: 60
K: 82
Pl: 3.6
K: 3.7
Valdes
(1991)
Chile HPT 24 RCT-DBX 23 Placebo KCl 4 64 Pl: 55
K: 123
Pl: 3.8
K: 4.1
Fotherby
(1992)
UK HPT 18
5 men
75 (66–79) RCT-DBX 26 Placebo KCl 4 60 Pl: 60
K: 99
Pl: 4.3
K: 4.4
Continued
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Table 1 Continued
Author
(year) Country Population
Participants
(n)
Age
(range),
years Design Quality* Control Potassium
Duration
(weeks)
Quantity
of K
(mmol/day)
Urinary K
(mmol/day)
Plasma/
serum K
(mmol/L) Comment
Geleijnse
(1994)
The
Netherlands
General
population
100 (55–75) RCT-DBP 24 Control
(common
salt)
KCl
(mineral salt)
24 22 Pl: 86
K: 97
Pl: 4.23
K: 4.35
Mineral salt:
41% KCl, 17%
Mg salt, 1%
trace minerals
Kawano
(1998)
Japan HPT 55
26 men
62.3 (36–77) RCT-DBX 20 Placebo KCl (slow-K) 4 64 Pl: 54
K: 96
Pl: 4.15
K: 4.42
He (2010) UK HPT 42
30 men
51 (18–75) RCT-DBX 26 Placebo KCl (slow-K)
KHCO3
4
4
64
64
Pl: 77
KCl: 122
KHCO3:
125
Pl: 4.4
KCl: 4.6
KHCO3: 4.4
Yusuf
(2012)
India High risk 518
308 men
57.5 RT-Open
label
16 None KCl 8 30 –
–
Pre: 4.3
K: 4.4
Graham
(2014)
North
Ireland
HPT
CVD>10%
40
32 men
54.8 (40–70) RCT-DBX 23 Placebo KCl (slow-K) 6 64 –
–
Pl: 3.9
K: 4.1
On doxazosin;
6 weeks
washout
Gijsbers
(2015)
The
Netherlands
Non-smokers 36
24 men
white
65.8
(47–80)
RCT-DBX 25 Placebo KCl capsules 4 72 Pl: 55.3
K: 118.1
Pl: 4.29
K: 4.41
Untreated
*Downs and Black score (max 27).
C, control; DB, double blind; HPT, hypertension; K, potassium; P, parallel group; Pl, placebo; RCT, randomised controlled trial; SB, single blind; X, crossover.
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24 weeks and the amount of K given from 22 to
140 mmol/day.
The effect of potassium supplementation on plasma
and serum potassium
In the pooled analysis, K supplementation caused a
small increase in plasma or serum K levels (WMD
0.14 mmol/L, 95% CI 0.09 to 0.19, p<1×10−5) with no
evidence of publication bias (Egger’s test p=0.65), no
asymmetry detected by the ‘trim and ﬁll’ method (see
online supplementary S7) and some heterogeneity
between studies (I2=57%, p=6×10−4; ﬁgure 2). The
effects on plasma or serum K showed a signiﬁcant vari-
ation by dose given (test of subgroup differences:
p=0.02) (see online supplementary S8). However, it did
not appear that there was a dose-dependent effect
(meta-regression p=0.62; see online supplementary S9),
although most of the doses were in a narrow range of
50–75 mmol/day (see online supplementary S10 and
S11). The effect increased from 0.11 mmol/L (0.06,
016) in those without concomitant drug therapy to 0.17
(0.01, 0.34) and 0.42 (0.17, 0.68) in those with concomi-
tant drug therapy whether including or excluding
ACE-inhibitors (ACE-i) or angiotensin receptor blockers
(ARB) (test of subgroup differences: p=0.05; see online
supplementary S12). The greatest increase was seen in
two studies of hypokalaemic patients in whom the
objective was to restore their plasma levels.s3 s6 The
effects were not associated with the geographic area of
the world where trials were performed (test of subgroup
differences: p=0.13; see online supplementary S13) or
the average age of the participants (meta-regression
p=0.82; see online supplementary S14). To rule out the
inﬂuence of poor-quality trials on the overall estimate,
we repeated the analysis only in double-blind rando-
mised placebo-controlled crossover trials (n=12). The
estimate of effect was 0.19 mmol/L (95% CI 0.12 to
0.25, p<1×10−5; I2=42%, p=0.05). We also estimated the
pooled effect in trials of hypertensive patients only
(n=16; WMD 0.19 mmol/L, 95% CI 0.13 to 0.26,
p<1×10−5; I2=49%, p=0.01).
The effect of potassium supplementation on urinary
potassium excretion
K supplementation caused a signiﬁcant increase in
urinary K excretion (WMD 45.75 mmol (1784 mg) per
day, 95% CI 37.81 to 53.69, p<1×10−5; ﬁgure 3). The
dose of K had a signiﬁcant effect on the change in
urinary K (meta-regression p=0.001; ﬁgure 4). While
conﬁrming that the urinary excretion of K is a good bio-
marker of K intake, most studies used between 48 and
100 mmol of K per day, with only 2 studies of those pro-
viding urinary potassium below and above these
levels.s2 s15 When these studies were removed in a sensi-
tivity analysis, the effect remained virtually unchanged
(WMD 46.04 mmol (1795 mg) per day, 95% CI 39.33 to
52.75, p<1×10−5).
The effect of potassium supplementation on plasma
and serum creatinine
K supplementation did not cause any change in renal
function as measured by serum or plasma creatinine
levels (WMD 0.30 µmol/L, 95% CI −1.19 to 1.78,
p=0.70; ﬁgure 5). There was some publication bias
(Egger’s test p=0.047); however, the ‘trim and ﬁll’
method did not show asymmetry in the funnel plot (see
Figure 2 Forest plot of the effect of potassium supplementation on serum or plasma potassium levels in randomised clinical
trials.
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online supplementary 15). No heterogeneity was
detected (I2=9%, p=0.35).
The effect of potassium supplementation on urinary
sodium excretion
K supplementation did not cause a signiﬁcant change in
urinary sodium excretion (WMD 4.42 mmol (75.2 mg)
per day, 95% CI −4.84 to 13.69, p=0.35) (see online sup-
plementary S16). However, there was heterogeneity
between studies (I2=55%, p=0.003), fully accounted for
by one study (using a salt substitute)s15. When removed,
a small natriuretic effect of K was detected (WMD
7.42 mmol (126.1 mg) per day, 95% CI 1.26 to 13.58,
p=0.02; see online supplementary S17) (I2=0%, p=0.86).
Tolerability
No serious hazardous side effects were reported in any
trial (table 2).
DISCUSSION
In the present meta-analysis of RCTs, increasing K intake
by moderate K supplementation (average 45 mmol
(1755 mg) per day) causes a small increase in serum
K levels (0.17 mmol/L) and no change in renal function.
The effect on serum K does not vary with the dose given
(from 22 to 140 mmol (from 858 to 5460 mg) per day),
with the duration of the supplementation (2–24 weeks),
the presence or absence of concomitant drug therapy,
including the presence of blockers of the renin–
angiotensin system, and with age or geographic location.
To the best of our knowledge, this is the ﬁrst study
evaluating the safety of increasing K intake with supple-
ments on serum K and renal function, based on RCTs.
Strengths and limitations
Our analysis followed the CONSORT guidelines and
assessed the risk of bias qualitatively and quantitatively.
As none of the trials had been designed to assess the
effect of K supplements on serum K and creatinine as
primary outcomes, the studies may have been underpow-
ered for an effect of these variables. However, given the
narrow variability of these measurements and the stand-
ard laboratory methods used to determine them, the
meta-analytical approach will have compensated by
giving more statistical power for the pooled estimates.
The source of heterogeneity was identiﬁed in three
trials. However, their removal, while removing the het-
erogeneity, did not alter substantially the pooled esti-
mate. These results add to previous evidence of safety of
these supplements on other biomarkers like total choles-
terol, triglyceride and catecholamine levels.1
RCTs and systematic reviews are reliable methods of
determining the effects of treatment.23 Their usefulness
in providing evidence that would inﬂuence practice
would depend on their internal validity (their quality in
Figure 3 Forest plot of the effect of potassium supplementation on urinary potassium excretion in randomised clinical trials.
Figure 4 Meta-regression analysis of the changes in urinary
potassium excretion for the dose of potassium given.
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design and conduct to minimise erroneous conclusions)
and their external validity (their applicability and gener-
alisability in clinical settings).23 24 Lack of external vali-
dity has always been the most frequent criticism by
clinicians of RCTs, systematic reviews and guidelines.23 It
has been argued that the results of trials should be
assumed to be externally valid unless there are speciﬁc
reasons to put this assumption into signiﬁcant doubt.23
Most trials included in the meta-analysis (16 out of 20)
were carried out in people with hypertension, while in 2
studies on diuretics and with hypokalaemia.s3 s6 The
remainder were carried out in normotensives,s10 a high-
risk group,s18 non-smokerss20 and in a random sample of
the general population.s15 The results are therefore gen-
eralisable to this type of participants only. The reviewed
trials had not included people or patients with renal
impairment. Sensitivity analyses did not suggest differ-
ences according to patients’ characteristics like gender,
age and type of underlying condition. However, these
subgroup analyses have limited margin of interpretation.
For instance, only 3 studies were conducted in patients
with a mean age of >60 years.s14 s16 s20 In individual
trials, irrespective of dose of K, duration of supplementa-
tion or the presence and type of concomitant pharmaco-
logical therapy, changes in serum K were below
0.3 mmol/L, with the exception of 2 studies.s6−s7 In one
study,s6 patients were selected on the basis that they had
clinically signiﬁcant diuretic-induced hypokalaemia; the
supplementation increased serum K by 0.56 mmol/L,
restoring it within the normal range. In another study,s7
only black women were recruited who had lower K
intake (urinary excretion 52 mmol (2028 mg) per day)
and a tendency to lower serum K (3.87 mmol/L). The
supplementation increased serum K by 0.45 mmol/L
with levels within the normal range.
What is the evidence of hazard?
Some international bodies discourage the use of K sup-
plements or K-rich salt replacers as likely cause of hazard-
ous hyperkalaemia.2 12–17 Generally, these warnings, while
applied to the general population, are based on case
reports referring to either sick patients with end-stage
kidney disease ignoring medical advice on K intake
restrictions or excessive intakes leading to increases in
serum K levels of several millimoles per litre with severe
hyperkalaemia.25–31 In 5 cases,30 31 individuals suffered
serious hyperkalaemia and in 2 cases fatal hyperkalaemia
(serum K 8.9 and 10.8 mmol/L) following K overdoses of
up to 723 mmol (28 200 mg) in a day. In other
reports,25 26 28 29 individuals with severe renal impairment
and, in some cases, already of haemodialysis28 abused
K-containing salt substitutes. Finally, 2 Afro-Caribbean
men on antihypertensive therapy including ACE-
inhibitors27 presented with serum K levels of 7.6 and
7.0 mmol/L following daily use of 70 mmol (2730 mg)
and 133 mmol (5187 mg) of K added to their food daily
as a salt substitute. We agree that caution should be exer-
cised in people with severe impairments of their renal
function when considering potassium supplements.
However, our analysis suggests that a more ‘moderate’
supplement does not seem to cause severe hyperkalaemia
or deterioration in renal function in people with normal
renal function, even in the presence of drugs that block
the renin–angiotensin–aldosterone system.
Benefits of potassium supplements
The consideration of the use of moderate increases in K
intake with supplements is encouraged by the evidence
of potential beneﬁts in controlling hypertension,1 4–6 a
surrogate end point for cardiovascular risk, stroke in par-
ticular. While the evidence of a potential beneﬁt of K on
stroke prevention in humans is mainly derived from
observational cohort studies,1 3–6 early animal experi-
ments indicated that the reduction in mortality of stroke-
prone hypertensive rats given K supplements was seen
even in BP-matched animals,32 33 suggesting that, in rats,
K reduces stroke rates also through mechanisms other
than BP reduction. Subsequent evidence showed a pro-
tective vascular effects of K, especially in thrombus for-
mation.7 High K increases the lumen of cerebral
Figure 5 Forest plot of the effect of potassium supplementation on serum or plasma creatinine levels in randomised clinical
trials.
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arteries,34 inhibition of atherosclerotic vascular lesions,
decreases vascular smooth muscle cell proliferation and
migration, decreases free radical formation, reduces
LDL-cholesterol oxidation and decreases platelet aggre-
gation.35 36 These results have supported recent calls for
considering trials of a moderate increase in K intake
with supplements to test whether this is a viable and
potentially cost-effective strategy to prevent stroke inci-
dence in high-risk groups and stroke recurrence.7
How can we increase potassium intake?
Increasing K intake through diet is an efﬁcacious
method to lower BP.37 It would involve increasing the
consumption of K-rich foods like fruits, vegetables,
beans and nuts.8 While the dietary approach is the basis
of public health programmes promoting healthy eating,
it is generally costly and difﬁcult to implement in low
socioeconomic groups38 39 as well as among vulnerable
patients at high risk, like elderly people who may ﬁnd it
difﬁcult to change their diet, and would widen health
inequalities. The addition of K through salt substitutes
or supplements is an alternative cheap intervention to
achieve daily targets. The quantity of K can be titrated
more precisely, and it is acceptable to many people.
Caution should be exercised in people who suffer from
kidney disease and have renal dysfunction, or in those
who may be on antialdosterone therapy.
CONCLUSIONS
The present study shows that a moderate increase in K
intake using supplements could be safe and void of risk
of hazardous hyperkalaemia or renal deterioration in
Table 2 Tolerability of potassium supplementation and reported adverse reactions in the published papers
Study Description
MacGregor (1982) All patients who entered the trial completed it without any adverse effect.
Richards (1984) The study was completed without incident.
Bulpitt (1985) The patients were asked about any symptom of indigestion. Three reported of the symptom before
being given K supplementation but not afterwards, and one patient in the control group lost this
symptom. One patient in each group started to complain of a decrease in appetite at the end of the trial.
Kaplan (1985) None of the 16 patients had notable changes in clinical status or symptoms during the 16-week trial.
Smith (1985) Nothing reported. No withdrawals.
Zoccali (1985) Four patients were withdrawn, one because the first treatment (Selora salt) precipitated diarrhoea, two
because they were unable to tolerate the taste of the K preparation and one because the diastolic BP
after the placebo phase had risen to 120 mm Hg. Twelve patients interviewed after the study
commented on the unpleasant taste of the K preparation.
Matlou (1986) Three patients dropped out, one was admitted to hospital with an intercurrent illness and was given
moduretic, and two failed consistently to keep their appointments.
Grobbee (1987) Nothing reported. All participants entering the double-blind study completed it.
Siani (1987) All patients completed the trial without suffering any adverse effects.
Barden (1987) Forty-three women completed the trial, with one withdrawing during the first treatment period.
Obel (1989) All 48 patients completed the trial. None developed any notable untoward effect attributable to
medication.
Patki (1990) Three patients given placebo, four given K, and four given K and Mg reported of pain in the abdomen
and nausea, but this passed off and did not require withdrawal of treatment.
Valdes (1991) Nothing reported.
Fotherby (1992) There were no withdrawals from the study. All patients took at least 90% of the trial medication (…)
which was well tolerated with no reported adverse effects.
Geleijnse (1994) Complete follow-up was achieved by 97 of the 100 randomised participants. Two of the controls
withdrew after 8 and 16 weeks because of admission to hospital for symptoms not related to
intervention. One person withdrew in the mineral salt group after 6 weeks because of dislike of the
foods. (…) Reports of side effects and lifestyle changes during intervention were minimal and equally
distributed among the study groups.
Kawano (1998) One patient withdrew due to gastrointestinal symptoms during K supplementation.
He (2010) Four patients withdrew from the study (reasons not given).
Yusuf (2012) Twenty-seven (10.5%) of those receiving K+ supplements permanently discontinued this (11 for
dyspepsia, 4 for elevated creatinine or K+, 12 for other reasons).
Graham (2014) The main side effect was that of gastrointestinal irritation. This was reported by four participants, while
taking potassium chloride. Symptoms resolved with a reduction in potassium supplementation from
64 mmol/4.8 g (8 tablets) to 48 mmol/3.6 g daily (6 tablets). No participant withdrew from the study as a
result of this side effect.
Gijsbers (2015) Reported side effects in participants’ diaries indicated that 19 persons experienced gastrointestinal
symptoms during sodium, 21 during potassium and 8 during placebo supplementation (P=0.004). Other
side effects including dizziness, headache, illness, shortness of breath and oedema were not
significantly different among the three treatments.
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people and patients whose kidney function is not
impaired, even using blockers of the renin–angiotensin
system. Given the limitations of the analysis to younger
patient groups and short-term supplementations, and
the potential beneﬁt as an adjunct preventive strategy,7
these results should encourage feasibility trials to ascer-
tain the generalisability of these ﬁndings to patients with
normal renal function at high risk of stroke.
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